MX342000B - Peptidos ect2 y vacunas que los incluyen. - Google Patents

Peptidos ect2 y vacunas que los incluyen.

Info

Publication number
MX342000B
MX342000B MX2012011385A MX2012011385A MX342000B MX 342000 B MX342000 B MX 342000B MX 2012011385 A MX2012011385 A MX 2012011385A MX 2012011385 A MX2012011385 A MX 2012011385A MX 342000 B MX342000 B MX 342000B
Authority
MX
Mexico
Prior art keywords
cancer
peptides
nucleic acids
substances
compositions
Prior art date
Application number
MX2012011385A
Other languages
English (en)
Other versions
MX2012011385A (es
Inventor
Nakamura Yusuke
Ohsawa Ryuji
Tsunoda Takuya
Yoshimura Sachiko
Watanabe Tomohisa
Original Assignee
Oncotherapy Science Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc * filed Critical Oncotherapy Science Inc *
Publication of MX2012011385A publication Critical patent/MX2012011385A/es
Publication of MX342000B publication Critical patent/MX342000B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a péptidos aislados derivados de la SEC ID NO: 42 y sus fragmentos que se acoplan a un antígeno HLA e inducen a los linfocitos T citotóxicos (CTL) y que por ende pueden ser utilizados en el contexto de la inmunoterapia del cáncer, más particularmente en las vacunas anticancerosas. Los péptidos de la invención incluyen tanto las secuencias de aminoácidos citadas con anterioridad como sus versiones modificadas en las cuales uno, dos o varios aminoácidos son sustituidos, eliminados, insertados o añadidos, siempre que estas versiones modificadas conserven la necesaria capacidad de acoplamiento a HLA y/o de inducción de los CTL de las secuencias originales. Además se proporcionan ácidos nucleicos que codifican a cualquiera de los péptidos mencionados con anterioridad, al igual que agentes, sustancias y/o composiciones farmacéuticas que incluyen o incorporan cualquiera de los péptidos o ácidos nucleicos mencionados con anterioridad. Los peptidos, acidos nucleicos, agentes farmacéuticos, sustancias y composiciones de la presente invención encuentran particular utilidad en el tratamiento de los cánceres y tumores, lo que, por ejemplo, incluye el cáncer vesical, el cáncer de mama, el cáncer cervical, el carcinoma colangiocelular, la CML, el cáncer colorrectal, el cáncer esofágico, el NSCLC, el linfoma, el cáncer pancreático, el cáncer de próstata, el carcinoma renal y el SCLC.
MX2012011385A 2010-04-02 2011-03-30 Peptidos ect2 y vacunas que los incluyen. MX342000B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32057710P 2010-04-02 2010-04-02
PCT/JP2011/001909 WO2011122022A1 (en) 2010-04-02 2011-03-30 Ect2 peptides and vaccines including the same

Publications (2)

Publication Number Publication Date
MX2012011385A MX2012011385A (es) 2013-12-16
MX342000B true MX342000B (es) 2016-09-09

Family

ID=44711777

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012011385A MX342000B (es) 2010-04-02 2011-03-30 Peptidos ect2 y vacunas que los incluyen.

Country Status (20)

Country Link
US (1) US8951975B2 (es)
EP (1) EP2553096B1 (es)
JP (1) JP5816965B2 (es)
KR (1) KR101863557B1 (es)
CN (1) CN102939379B (es)
AR (1) AR081065A1 (es)
AU (1) AU2011233401B2 (es)
BR (1) BR112012024997B1 (es)
CA (1) CA2795318C (es)
CO (1) CO6571869A2 (es)
DK (1) DK2553096T3 (es)
EA (1) EA027940B1 (es)
ES (1) ES2655437T3 (es)
IL (1) IL222057A (es)
MX (1) MX342000B (es)
NZ (1) NZ603379A (es)
SG (1) SG184165A1 (es)
TW (2) TWI538685B (es)
WO (1) WO2011122022A1 (es)
ZA (1) ZA201207342B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
MY198087A (en) 2015-10-05 2023-07-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
AU6632496A (en) 1995-08-03 1997-03-05 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US7393663B2 (en) * 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
CA2425671A1 (en) * 2000-10-12 2002-04-18 Exelixis, Inc. Human ect2 and methods of use
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7227007B2 (en) * 2000-12-28 2007-06-05 Asahi Kasei Pharma Corporation NF-κB activating gene
WO2002072631A2 (en) 2001-03-14 2002-09-19 Dakocytomation Denmark A/S Mhc molecule constructs and their usesfor diagnosis and therapy
WO2002078524A2 (en) 2001-03-28 2002-10-10 Zycos Inc. Translational profiling
WO2002096943A1 (en) * 2001-05-25 2002-12-05 Asahi Kasei Kabushiki Kaisha Stat6-activating genes
US20030092616A1 (en) 2001-05-25 2003-05-15 Akio Matsuda STAT6 activation gene
JP2005506833A (ja) * 2001-06-04 2005-03-10 キュラジェン コーポレイション 抗原性ポリペプチドに結合する新規抗体、抗原をコード化する核酸、および使用方法
WO2002099062A2 (en) 2001-06-04 2002-12-12 Curagen Corporation Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2005019475A2 (en) 2003-08-20 2005-03-03 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
JP5109131B2 (ja) 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
US8053183B2 (en) 2005-07-27 2011-11-08 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
CN101283106A (zh) 2005-07-27 2008-10-08 肿瘤疗法科学股份有限公司 小细胞肺癌的诊断方法
US8003770B2 (en) 2005-09-13 2011-08-23 Mie University T-cell receptor and nucleic acid encoding the receptor
CN101432022A (zh) 2006-02-28 2009-05-13 肿瘤疗法科学股份有限公司 利用抗-EphA4抗体效应物作用损伤细胞的方法
CA2666559A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
CN101589058A (zh) 2006-10-20 2009-11-25 株式会社未来创药研究所 包含抗hb-egf抗体作为活性成分的癌症治疗剂
TWI610939B (zh) * 2007-02-21 2018-01-11 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
EP2105511A1 (en) 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
EP2321410A4 (en) * 2008-07-16 2011-09-14 Oncotherapy Science Inc ONCOGEN ECT2 AS A THERAPEUTIC TARGET AND PROGNOSTIC INDICATOR FOR LUNG AND SOPHAGE CANCER
TW201008574A (en) * 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same

Also Published As

Publication number Publication date
SG184165A1 (en) 2012-10-30
BR112012024997A2 (pt) 2017-05-23
EP2553096A4 (en) 2013-11-13
IL222057A (en) 2017-12-31
US8951975B2 (en) 2015-02-10
EA201291004A1 (ru) 2013-04-30
TW201627003A (zh) 2016-08-01
JP2013523082A (ja) 2013-06-17
KR101863557B1 (ko) 2018-06-01
CO6571869A2 (es) 2012-11-30
MX2012011385A (es) 2013-12-16
AU2011233401B2 (en) 2015-03-26
NZ603379A (en) 2014-09-26
US20130095128A1 (en) 2013-04-18
BR112012024997B1 (pt) 2022-03-22
WO2011122022A1 (en) 2011-10-06
EA027940B1 (ru) 2017-09-29
AU2011233401A1 (en) 2012-10-25
DK2553096T3 (en) 2018-01-15
ZA201207342B (en) 2013-06-26
TWI538685B (zh) 2016-06-21
AR081065A1 (es) 2012-06-06
CN102939379B (zh) 2016-08-03
EP2553096B1 (en) 2017-11-22
KR20130033367A (ko) 2013-04-03
JP5816965B2 (ja) 2015-11-18
TW201138803A (en) 2011-11-16
CN102939379A (zh) 2013-02-20
CA2795318A1 (en) 2011-10-06
CA2795318C (en) 2018-11-13
EP2553096A1 (en) 2013-02-06
ES2655437T3 (es) 2018-02-20

Similar Documents

Publication Publication Date Title
MX2022005060A (es) Novedosos peptidos y combinaciones de peptidos para usarse en la inmunoterapia contra el cancer de pulmon, incluido el cancer de pulmon no microcitico (nsclc) y otros canceres.
CR20210233A (es) NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419)
CR20200431A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (div. 1. 2018-74)
EP3545965A3 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
PH12018500004A1 (en) Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
MX2011008763A (es) Peptidos foxm1 y vacunas que contienen los mismos.
MX2012011668A (es) Peptidos cdca5 y vacunas que incluyen los mismos.
SG10201407944TA (en) Imp-3 oligopeptides and vaccines including the same
MX350220B (es) Peptidos de mphosph1 y vacunas que incluyen los mismos.
MX2013014489A (es) Peptidos sema5b y vacunas que incluyen los mismos.
MX355759B (es) Peptidos topk y vacunas que incluyen los mismos.
MX2012011385A (es) Peptidos ect2 y vacunas que los incluyen.
MX344579B (es) Peptidos hjurp y vacunas que incluyen los mismos.
MX2022005570A (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pancreas y otros tipos de cancer.
MX2013006014A (es) Peptidos tomm34 y vacunas que los incluyen.
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.
SG10201408245WA (en) Tmem22 peptides and vaccines including the same
MX2015007015A (es) Peptidos sema5b y vacunas que contienen los mismos.
EP2370454A4 (en) PEPTIDES WITH EPITAOPE WDRPUH AND VACCINES INCLUDING THEM
TH126648B (th) Ect2 เปปไทด์ และ วัคซีนที่รวมถึงสิ่งเดียวกันนั้น
TH126648A (th) Ect2 เปปไทด์ และ วัคซีนที่รวมถึงสิ่งเดียวกันนั้น

Legal Events

Date Code Title Description
FG Grant or registration